leflunomide has been researched along with Leishmaniasis, Cutaneous in 1 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide has been reported as an immunomodulating agent which acts on a variety of cells including T- and B-lymphocytes." | 1.29 | Protective effect of leflunomide on the natural course of Leishmania major-induced disease in genetically susceptible BALB/c mice. ( Asmuss, PA; Humborg, C; Röllinghoff, M; Solbach, W; Zimmermann, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solbach, W | 1 |
| Asmuss, PA | 1 |
| Zimmermann, S | 1 |
| Humborg, C | 1 |
| Röllinghoff, M | 1 |
1 other study available for leflunomide and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Protective effect of leflunomide on the natural course of Leishmania major-induced disease in genetically susceptible BALB/c mice.
Topics: Animals; Antiparasitic Agents; Antiprotozoal Agents; Female; Genetic Predisposition to Disease; Immu | 1995 |